Company insight
A global vision for medical moulding
High-precision injection moulding is essential for the manufacturing of many medical devices, but technology alone cannot meet the stringent quality levels demanded by today’s life sciences sector. Karl Stillman, vice-president, strategic sales, Rosti Group, explains how technological capability and manufacturing knowhow must go hand in hand with management capability and years of experience to fully satisfy the industry’s requirements.
What crucial role do injection moulding specialists play in the development of new and innovative medical devices? Karl Stillman: As an injection moulding specialist, our expertise and services are an integral part of the production process. We support our customers in navigating the complex landscape of medical device regulations, ensuring products meet necessary standards for safety and effectiveness. To do so, we partner with customers in delivering customised, high-precision devices. This is particularly important since medical devices often need to be carefully tailored to ensure the uniformity and functionality of intricate and complex parts. This is crucial for devices like insulin pens, catheters and components for specialised surgical instruments. A contract manufacturer often plays an important role in providing material expertise, since medical devices require biocompatible polymers, elastomers, liquid silicone rubber and many other materials. It is important to choose the right materials to ensure that regulatory standards for safety and performance, as well as stringent quality and sterilisation standards are met.
Why is it important to have an experienced contract manufacturer handling the injection moulding process? Medical devices containing moulded thermoplastic components benefit from a trusted partner like Rosti because we have more than 75 years’ experience in delivering value to the medical sector. That can be of paramount importance in navigating the complex regulatory landscape, as well as delivering consistent high-quality production processes, in which it is crucial to adhere to strict standards. We make sure that costly
delays, legal issues and all other associated risks are mitigated.
As an experienced global manufacturer, Rosti is able to scale up production to meet demand while maintaining consistent quality. Also, we view innovation as highly important, and our three strategically located innovation centres make us a strong partner in the innovation and design phase, which drastically reduces time to market.
How have your customers’ needs changed, and how is Rosti able to evolve alongside its customers? We have seen trends such as an increased production outsourcing, where CDMOs have come to play a more important role as a partner to OEMs. We are also seeing a nearshoring trend, and as a global organisation Rosti can support customers investigating new supply chain set-ups. Through accredited facilities, experienced people, and state-of-the art equipment, we can walk the extra mile to exceed customer expectations.
You note that Rosti is a global organisation, so how important is it for a contract manufacturer to have a global footprint? With the same quality and standards across all our sites, we can speak to customers in one voice and give them one contact for our entire organisation. Moreover, a global footprint and a ‘One Rosti’ organisation enables us to help customers access and enter new markets, find optimal and diversified supply chain solutions and minimise the risk of supply chain disruptions. Calling on local presence and expertise in all the main medical markets in the world, we provide a deeper understanding of the regional regulations, standards and market preferences.
Medical Device Developments /
www.nsmedicaldevices.com
Can you give examples of Rosti’s involvement in the manufacture of innovative medical devices? Our three innovation centres – in Asia, Europe and North America – support customers in shortening time to market and offering injection moulded prototypes within 72 hours. Recently, we helped a customer with full delivery from concept to reality of a Class II active medical device for the US market via the 510k pathway. We supported the client from the design phase, through proof of concept to product verification and finally mass production.
How does Rosti’s global technology roadmap help to bring new technologies to a technically ready stage more quickly? We have continuously invested time, money, and engineering expertise to develop and enhance our roadmap. We use an established technology readiness levels (TRLs) development process, originally developed by Nasa, to show how mature a technology is and when it can be used in production. It rigorously scrutinises each developmental stage to ensure only the best-fit and commercially viable are put into production.
Rosti works across many industries, but what makes it a good partner for life sciences companies? Our in-house knowledge of the regulatory environment in key markets helps our customers to navigate a highly complex regulatory landscape. As a leading medical CDMO, our aim is to support our customers from concept to reality, be a trusted partner in navigating the medical landscape and bring market leading innovation to our customers. ●
www.rosti.com 45
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146
